Introduction

62
Epstein-Barr virus (EBV) is a -herpesvirus that establishes latent infection in over 95%
135
Although the p27 S10A/S10A knock-in by itself was previously shown to have no effect on tumor-free Fig 3A) , compatible with the similar tumor onset observed in these two genotypes.
166
These data show that blocking both p27 Kip1 degradation pathways together has a synergistic 167 effect on halting G 1 -S phase cell cycle transition, and that this synergy is specific to LMP2A/-
168
MYC mice.
169
The p27 Super genotype also prevented the splenomegaly observed in LMP2A/-MYC 170 mice. As previously shown(24, 27), LMP2A/-MYC mice at 4-5 weeks old displayed significantly 171 higher spleen weight relative to body weight than WT mice (Fig. 3B) . The LMP2A/-
172
MYC/p27
Super mice, however, had spleen-to-body weight ratios that were not significantly 173 different from WT mice (Fig. 3B) . 
226
MYC mice, which was partially attenuated by blocking Cks1-dependent p27 Kip1 degradation(27).
227
As noted in the Introduction, our previous attempts to delay tumor onset in LMP2A/-MYC and
228
-MYC mice by blocking S10 phosphorylation alone were unsuccessful. In the current study, we 229 delayed tumor onset by blocking both Cks1-dependent and S10 phosphorylation-dependent (Fig. 3A) and the splenomegaly 246 observed in LMP2A/-MYC mice was normalized in LMP2A/-MYC/p27 Super mice (Fig. 3B ).
247
Additionally, B cell follicle formation is partially restored in LMP2A/-MYC/p27 Super pretumor 248 spleens (Fig. 3C) . The increased p27 Kip1 expression observed in LMP2A/-MYC/p27 Super and -
249
MYC/p27
Super splenic B cells (Fig. 3D ) is maintained in tumors from both genotypes (Fig 4B) ,
250
suggesting these tumors develop independently of p27 Kip1 degradation. Interestingly, in the 251 absence of -MYC, p27 Super does not affect splenic B cell number (Fig. 1A) and does not 252 decrease the percentage of S-phase B cells (Fig. 3A) or spleen-to-body ratio (Fig 3B) differ between these two models, as well as between the LMP2A/-MYC and -MYC models in 270 general.
271
Our current studies indicate the requirement that both pathways of p27 Kip1 degradation 272 be blocked to fully prevent the accelerated tumorigenesis driven by LMP2A. Overall, our results
273
show that normalizing G 1 -S phase cell cycle progression by elevating levels of p27 Kip1 both
274
delays Myc-driven lymphoma, and offsets the contribution of LMP2A in accelerating tumor 275 development. Our study points to both the nuclear and cytoplasmic pathways of p27 
292
Tumor, spleen, and bone marrow cell isolation
293
Pretumor splenic B cells were purified using the Mouse Pan-B Cell Isolation Kit by StemCell
294
Technologies. Bone marrow cells were flushed from femurs and tibia. Tumor-bearing lymph 295 node cells were prepared as previously described (22, 24, 36 
489
Blots and statistics were performed as described in Figure 3 . Data represent the mean +/-SD. * 490 p<0.05.
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